XOMA vs NUVL

XOMA Royalty Corp.

(XOMA) offers the better valuation at 28. 3x trailing P/E (53. 3x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to +30. 0% for XOMA Royalty Corp. (XOMA). Over 10 years, the gap is even starker: NUVL returned +461. 5% versus XOMA's +190. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nuvalent, Inc.

(NUVL) is the lower-risk stock at 1. 01β versus XOMA Royalty Corp. 's 1. 16β — meaning XOMA is approximately 14% more volatile than NUVL relative to the S&P 500.

On earnings-per-share growth, the picture is similar: XOMA Royalty Corp.

grew EPS 188. 5% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus 0. 0% for Nuvalent, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMA leads at 21. 8% versus 0. 0% for NUVL. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVL: 41.

0% to $144. 40.

In this comparison, XOMA (0.

7% yield) pays a dividend. NUVL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XOMA Royalty Corp.

(XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16), 0. 7% yield, +190. 9% 10Y return). Both have compounded well over 10 years (XOMA: +190. 9%, NUVL: +461. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XOMA is a small-cap high-growth stock; NUVL is a small-cap quality compounder stock. XOMA pays a dividend while NUVL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.